Table 9 Results of network meta-analysis of FVC (% predicted) absolute change from baseline
Ambrisentan | |||||||
|---|---|---|---|---|---|---|---|
-1.51 (-8.62,5.60) ⊕⊕⊝⊝low2,4 | Warfarin | ||||||
-2.40 (-8.73,3.93) ⊕⊕⊕⊝moderate2 | -0.89 (-4.14,2.36) ⊕⊕⊕⊝moderate2 | Placebo | |||||
-2.79 (-9.59,4.01) ⊕⊕⊝⊝low2,4 | -1.28 (-5.37,2.81) ⊕⊕⊝⊝low2,4 | -0.39 (-2.88,2.10) ⊕⊕⊕⊕high | Sildenafil | ||||
-4.70 (-11.92,2.52) ⊕⊕⊝⊝low2,4 | -3.19 (-7.95,1.57) ⊕⊕⊝⊝low2,4 | -2.30 (-5.79,1.19) ⊕⊕⊕⊕high | -1.91 (-6.19,2.37) ⊕⊕⊕⊝moderate4 | Nintedanib | |||
-5.05 (-12.12,2.01) ⊕⊕⊝⊝low2,4 | -3.54 (-8.06,0.97) ⊕⊕⊝⊝low2,4 | -2.65 (-5.79,0.49) ⊕⊕⊕⊕high | -2.26 (-6.30,1.77) ⊕⊕⊕⊝moderate4 | -0.35 (-5.04,4.34) ⊕⊕⊕⊝moderate4 | Pirfenidone | ||
-6.30 (-13.77,1.17) ⊕⊝⊝⊝very low1,2,4 | -4.79 (-9.93,0.35) ⊕⊝⊝⊝very low1,2,4 | -3.90 (-7.88,0.08) ⊕⊕⊕⊝moderate1 | -3.51 (-8.20,1.18) ⊕⊕⊝⊝low1,4 | -1.60 (-6.89,3.69) ⊕⊕⊝⊝low1,4 | -1.25 (-6.31,3.82) ⊕⊕⊝⊝low1,4 | PRM151 | |
-6.70 (-14.50,1.10) ⊕⊕⊝⊝low2,4 | -5.19 (-10.79,0.41) ⊕⊕⊝⊝low2,4 | -4.30 (-8.86,0.26) ⊕⊕⊕⊕high | -3.91 (-9.10,1.28) ⊕⊕⊕⊝moderate4 | -2.00 (-7.74,3.74) ⊕⊕⊕⊝moderate4 | -1.65 (-7.18,3.89) ⊕⊕⊕⊝moderate4 | -0.40 (-6.45,5.65) ⊕⊕⊝⊝low1,4 | Pamrevlumab |